PL3104939T3 - Leczenie jodkiem sodu zawału serca i urazu niedokrwiennego - Google Patents

Leczenie jodkiem sodu zawału serca i urazu niedokrwiennego

Info

Publication number
PL3104939T3
PL3104939T3 PL15746855.4T PL15746855T PL3104939T3 PL 3104939 T3 PL3104939 T3 PL 3104939T3 PL 15746855 T PL15746855 T PL 15746855T PL 3104939 T3 PL3104939 T3 PL 3104939T3
Authority
PL
Poland
Prior art keywords
treatment
sodium iodide
heart attack
ischemic injury
ischemic
Prior art date
Application number
PL15746855.4T
Other languages
English (en)
Inventor
Mark B. Roth
Michael L. MORRISON
Akiko Iwata
Original Assignee
Fred Hutchinson Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fred Hutchinson Cancer Center filed Critical Fred Hutchinson Cancer Center
Publication of PL3104939T3 publication Critical patent/PL3104939T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/16—Fluorine compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/18—Iodine; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
PL15746855.4T 2014-02-10 2015-02-10 Leczenie jodkiem sodu zawału serca i urazu niedokrwiennego PL3104939T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461937943P 2014-02-10 2014-02-10
US201462007015P 2014-06-03 2014-06-03
US201462060338P 2014-10-06 2014-10-06
US201462082957P 2014-11-21 2014-11-21
PCT/US2015/015227 WO2015120458A1 (en) 2014-02-10 2015-02-10 Halogen treatment of heart attack and ischemic injury

Publications (1)

Publication Number Publication Date
PL3104939T3 true PL3104939T3 (pl) 2024-09-30

Family

ID=53778544

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15746855.4T PL3104939T3 (pl) 2014-02-10 2015-02-10 Leczenie jodkiem sodu zawału serca i urazu niedokrwiennego

Country Status (16)

Country Link
US (4) US10201570B2 (pl)
EP (1) EP3104939B1 (pl)
JP (2) JP6573620B2 (pl)
KR (1) KR102304113B1 (pl)
CN (1) CN106102836B (pl)
AU (1) AU2015213577B2 (pl)
CA (1) CA2937800C (pl)
ES (1) ES2987484T3 (pl)
IL (1) IL246431B (pl)
MX (1) MX386702B (pl)
NZ (1) NZ721500A (pl)
PL (1) PL3104939T3 (pl)
PT (1) PT3104939T (pl)
RU (1) RU2728790C2 (pl)
WO (1) WO2015120458A1 (pl)
ZA (1) ZA201604785B (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX386702B (es) * 2014-02-10 2025-03-19 Fred Hutchinson Cancer Center Tratamiento con halogeno de ataque cardiaco y lesion isquemica.
NZ729754A (en) 2014-09-29 2023-01-27 Hutchinson Fred Cancer Res Compositions, kits, and methods to induce acquired cytoresistance using stress protein inducers
WO2017173308A1 (en) 2016-03-31 2017-10-05 Goergetown University Radiation mitigator and method of use thereof
IL264725B2 (en) * 2016-08-11 2023-03-01 Sulfilatec Inc Preparations and methods for treating the disease
US20190358242A1 (en) * 2017-02-08 2019-11-28 Fred Hutchinson Cancer Research Center Compositions, kits, and methods to induce acquired cytoresistance using stress protein inducers
JP7237366B2 (ja) 2017-12-29 2023-03-13 国立大学法人大阪大学 アスタチン溶液及びその製造方法
EP3801565A4 (en) * 2018-06-08 2022-04-06 Faraday Pharmaceuticals, Inc. USE OF HALOGENATED COMPOUNDS FOR THE TREATMENT AND PREVENTION OF TISSUE DAMAGE AND POST-INTENSIVE CARE SYNDROME
US12313635B2 (en) 2018-07-27 2025-05-27 The Regents Of The University Of California Biomarker for thoracic aortic aneurysm
RU2712448C1 (ru) * 2019-05-14 2020-01-29 Федеральное Государственное Бюджетное Научное Учреждение "Федеральный Научно-Клинический Центр Реаниматологии и Реабилиталогии" (ФНКЦ РР) Способ кардиопротекции ишемических и реперфузионных повреждений в остром периоде инфаркта миокарда
CN110331162B (zh) * 2019-06-12 2021-02-19 温州医科大学 一种主动脉夹层特异性诱导多能干细胞及疾病模型应用
JP2023500702A (ja) * 2019-11-04 2023-01-10 ファラデイ ファーマシューティカルズ， インコーポレイテッド 化学療法に関連した悪液質および心毒性の治療ならびに予防のためのヨウ化化合物の使用
CN112136765B (zh) * 2020-09-29 2022-03-29 河南省农业科学院畜牧兽医研究所 一种猪卵巢氧化应激模型及其构建方法和用途

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5364555A (en) 1991-04-30 1994-11-15 Advanced Oxygen Technologies, Inc. Polymer compositions containing salicylic acid chelates as oxygen scavengers
US6458758B1 (en) 1993-08-16 2002-10-01 Synzyme Technologies, Inc. Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5688665A (en) 1994-01-07 1997-11-18 Fred Hutchinson Cancer Research Center Isolated nucleic acid molecules encoding the p27 KIP-1 protein
US6316208B1 (en) 1994-01-07 2001-11-13 Memorial Sloan-Kettering Cancer Center Methods for determining isolated p27 protein levels and uses thereof
AU2770695A (en) 1994-07-15 1996-02-16 Fred Hutchinson Cancer Research Center Isolated p27 protein and methods for its production and use
EP0877796A4 (en) 1996-01-18 2002-01-02 Hutchinson Fred Cancer Res COMPOSITIONS AND METHODS FOR MEDIATING THE PROGRESS OF THE CELL CYCLE
CA2650204A1 (en) 1996-12-31 1998-07-09 Harry B. Demopoulos Pharmaceutical preparations of glutathione and methods of administration thereof
US6248335B1 (en) 1997-10-29 2001-06-19 Symbollon Corporation Stabilized oral pharmaceutical composition containing iodide and iodate and method
US5885592A (en) * 1997-10-29 1999-03-23 Symbollon Corporation Methods and pharmaceutical compositions for oral delivery of molecular iodine
GB0022922D0 (en) * 2000-09-19 2000-11-01 Chapman Robert E Compounds for use in medicine
US6534676B2 (en) * 2001-01-31 2003-03-18 The Arizona Board Of Regents On Behalf Of The University Of Arizona Method to treat chronic heart failure and/or elevated cholesterol levels using 3,5-diiodothyropropionic acid and method to prepare same
US6716877B2 (en) * 2001-01-31 2004-04-06 The Arizona Board Of Regents On Behalf Of The University Of Arizona Method to treat chronic heart failure and/or elevated cholesterol levels
WO2002101018A2 (en) 2001-06-11 2002-12-19 Fred Hutchinson Cancer Research Center Methods for inducing reversible stasis
WO2003007992A1 (en) * 2001-07-18 2003-01-30 Ono Pharmaceutical Co., Ltd. Remedies for brain ischemic diseases
US7169377B2 (en) * 2003-10-15 2007-01-30 Wei Edward T Radioligands for the TRP-M8 receptor and methods therewith
EP1684580A2 (en) 2003-10-22 2006-08-02 Fred Hutchinson Cancer Research Center Methods, compositions and devices for inducing stasis in tissues and organs
US20050106214A1 (en) 2003-11-14 2005-05-19 Guohua Chen Excipients in drug delivery vehicles
AU2006249350B2 (en) 2003-11-19 2012-02-16 Metabasis Therapeutics, Inc. Thyromimetics for the treatment of fatty liver diseases
US20100048513A1 (en) 2008-08-20 2010-02-25 Hawkins Michael J Novel inhibitors of chymase
AU2006236150A1 (en) 2005-04-20 2006-10-26 Fred Hutchinson Cancer Research Center Methods, compositions and articles of manufacture for enhancing survivability of cells, tissues, organs, and organisms
GB0525504D0 (en) 2005-12-14 2006-01-25 Bristol Myers Squibb Co Antimicrobial composition
US20070265223A1 (en) 2006-03-10 2007-11-15 Ikaria, Inc. Compositions and methods of enhancing survivability and reducing injury of cells, tissues, organs, and organisms under hypoxic or ischemic conditions
US20080226750A1 (en) 2006-04-20 2008-09-18 Fred Hutchinson Cancer Research Center Methods, Compositions and Articles of Manufacture for Treating Shock and Other Adverse Conditions
US7589076B2 (en) 2006-05-18 2009-09-15 Pgx Health, Llc Substituted aryl piperidinylalkynyladenosines as A2AR agonists
WO2008005980A1 (en) * 2006-07-03 2008-01-10 Hill's Pet Nutrition, Inc. Copositions and methods for preventing or treating cardiovascular diseases in felines with hyperthyroidism
US20090011051A1 (en) 2006-09-28 2009-01-08 Roth Mark B Methods, Compositions and Articles of Manufacture for HIF Modulating Compounds
KR101538727B1 (ko) 2006-10-05 2015-07-22 이카리아 인코포레이티드 액체 칼코게나이드 조성물 및 이의 제조방법과 사용방법
US20100143503A1 (en) 2006-12-22 2010-06-10 Ikaria, Inc. Combinations of nitric oxide and sulfide and methods of use and manufacture thereof
WO2008089439A2 (en) 2007-01-18 2008-07-24 Fred Hutchinson Cancer Research Center Methods and compositions for enhancing lifespan involving sirtuin-modulating compounds and chalcogenides
US7858379B2 (en) 2007-06-05 2010-12-28 Lynntech, Inc. Apparatus and method for determining the concentration of iodine-containing organic compounds in an aqueous solution
EP2155213A1 (en) 2007-06-15 2010-02-24 Ikaria, Inc. Compositions comprising sulfide alone or in combination with nitric oxide and their use to
WO2009003061A1 (en) 2007-06-25 2008-12-31 Fred Hutchinson Cancer Research Center Methods and compositions regarding polychalcogenide compositions
NZ586125A (en) 2007-11-12 2012-12-21 Bipar Sciences Inc Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents
JP5542064B2 (ja) 2008-01-22 2014-07-09 アライム ファーマシューティカルズ，インコーポレーテッド 組織の損傷に関連した疾患及び障害を予防及び治療する、組織保護ペプチド及びペプチド類似体
US7745150B2 (en) 2008-03-07 2010-06-29 The University Of Connecticut Methods for the detection and monitoring of congestive heart failure
MX2011003809A (es) 2008-10-16 2011-08-12 Ikaria Inc Composiciones y metodos para tratar o prevenir heridas hipoxica o isquemica.
US20100183748A1 (en) 2009-01-21 2010-07-22 Ikaria, Inc. Methods for Treating or Preventing Radiocontrast Agent Induced Kidney Injury
US8680151B2 (en) 2010-02-11 2014-03-25 Fred Hutchinson Cancer Research Center Compounds, compositions and methods for treating or preventing hypoxic or ischemic injury
MX2012012479A (es) 2010-04-28 2013-07-03 Osnat Ashur-Fabian Metodos, composiciones y accesorios para proporcionar un tratamiento terapeutico.
KR20140104406A (ko) 2011-06-28 2014-08-28 프레드 헛친슨 켄서 리서치 센터 호기-말 가스 모니터링 장치
WO2013138520A1 (en) 2012-03-13 2013-09-19 University Of Tennessee Research Foundation Composition and system for transdermal delivery
US9566301B2 (en) 2012-03-29 2017-02-14 Cxl Ophthalmics, Llc Compositions and methods for treating or preventing diseases associated with oxidative stress
BR112014030992A2 (pt) * 2012-06-13 2017-06-27 Hutchinson Fred Cancer Res composições compreendendo calcogenetos e métodos relacionados
MX386702B (es) 2014-02-10 2025-03-19 Fred Hutchinson Cancer Center Tratamiento con halogeno de ataque cardiaco y lesion isquemica.
US9428470B2 (en) 2014-02-13 2016-08-30 Takeda Pharmaceutical Company Limited Heterocyclic compound
CN106093215B (zh) 2016-05-26 2019-09-06 深圳合核环境科技有限公司 一种测量水中溶解性有机卤含量的方法及系统
US20200096496A1 (en) 2017-06-14 2020-03-26 Faraday Pharmaceuticals, Inc. Iodide detection in blood plasma samples
EP3801565A4 (en) 2018-06-08 2022-04-06 Faraday Pharmaceuticals, Inc. USE OF HALOGENATED COMPOUNDS FOR THE TREATMENT AND PREVENTION OF TISSUE DAMAGE AND POST-INTENSIVE CARE SYNDROME
JP2023500702A (ja) 2019-11-04 2023-01-10 ファラデイ ファーマシューティカルズ， インコーポレイテッド 化学療法に関連した悪液質および心毒性の治療ならびに予防のためのヨウ化化合物の使用
WO2021257806A1 (en) 2020-06-18 2021-12-23 Fred Hutchinson Cancer Research Center Iodide for treatment of nonthyroidal illness syndrome

Also Published As

Publication number Publication date
CN106102836A (zh) 2016-11-09
MX2016010328A (es) 2017-02-06
CA2937800C (en) 2024-04-16
AU2015213577A2 (en) 2016-08-04
RU2016136411A3 (pl) 2018-09-26
US20250367232A1 (en) 2025-12-04
US10201570B2 (en) 2019-02-12
JP6573620B2 (ja) 2019-09-11
CN106102836B (zh) 2020-02-04
JP2017507929A (ja) 2017-03-23
ES2987484T3 (es) 2024-11-15
US20200016194A1 (en) 2020-01-16
US12016880B2 (en) 2024-06-25
IL246431B (en) 2021-05-31
CA2937800A1 (en) 2015-08-13
KR102304113B1 (ko) 2021-09-24
NZ721500A (en) 2022-11-25
KR20160113624A (ko) 2016-09-30
JP2019194265A (ja) 2019-11-07
AU2015213577B2 (en) 2019-02-14
EP3104939A1 (en) 2016-12-21
RU2728790C2 (ru) 2020-07-31
AU2015213577A1 (en) 2016-07-07
MX386702B (es) 2025-03-19
EP3104939B1 (en) 2024-05-01
RU2016136411A (ru) 2018-03-15
PT3104939T (pt) 2024-07-17
US20160346323A1 (en) 2016-12-01
ZA201604785B (en) 2020-01-29
EP3104939A4 (en) 2017-10-04
IL246431A0 (en) 2016-08-31
WO2015120458A1 (en) 2015-08-13
US20220313730A1 (en) 2022-10-06

Similar Documents

Publication Publication Date Title
PL3104939T3 (pl) Leczenie jodkiem sodu zawału serca i urazu niedokrwiennego
IL252839A0 (en) Treatment of boils
GB201701673D0 (en) Methods of well treatment
SG11201609254YA (en) Therapeutic placental compositions, methods of making and methods of use
PL3467111T3 (pl) IncRNA do terapii i diagnozowania przerostu serca
IL247354B (en) Treatment of conditions related to excess insulin in the blood
IL250513A0 (en) Treatment of episode disorders
IL283335B (en) Dihydropyrimidine-2-one compounds and their medical use
ZA201804950B (en) Indolinones compounds and their use in the treatment of fibrotic diseases
ZA201607878B (en) Compositions and methods of treating cardiac fibrosis with ifetroban
IL254825A0 (en) Methods of treatment with Tesalisib
GB201416832D0 (en) Methods of treatment
IL250662A0 (en) Tissue protection devices for the treatment of heart failure and other conditions
HUE051442T2 (hu) Androgén-megvonásos terápia indukálta hõhullámok és csontveszteség kezelése cisz-klomifén alkalmazásával
GB2551047B (en) Improvements in or relating to methods of patient monitoring
GB2558547B (en) Actuatable paddle and methods of use
GB201410407D0 (en) Treatment of chagas disease
GB201417248D0 (en) Compostion and methods of treatment
GB201412010D0 (en) Treatment of hypertransaminasemia
TWM490338U (en) Improved structure of bat
GB201407806D0 (en) Treatment of fibrosis
GB201414857D0 (en) Medical device and method to assess cardiac function
GB201501800D0 (en) Treatment of medical conditions
ZA201504639B (en) Treatment of water
GB201403633D0 (en) Improvements in or relating to medical devices